enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
5.22 ^USD	-5.09%		+8.75%	+1.56%

Apr. 16	EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	CI
Apr. 09	EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	CI

HANCOCK JAFFE LABORATORIES, INC. : Submission of Matters to a Vote of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

September 16, 2020 at 05:29 pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 15, 2020, Hancock Jaffe Laboratories, Inc. (the "Company") completed a special meeting of stockholders (the "Special Meeting"). The number of shares of stock entitled to vote at the Special Meeting was 38,324,333 shares of common stock and 4,205,406 shares of Preferred Stock (the "Voting Stock"). The number of shares of Voting Stock present or represented by valid proxy at the Special Meeting was 34,841,123 shares or approximately 82% of the Voting Stock. At the Special Meeting, the Company's stockholders (i) approved an amendment to the Company's Amended and Restated Certificate of Incorporation (the "A&R Certificate of Incorporation") to increase the aggregate number of authorized shares of common stock by 200,000,000 shares from 50,000,000 to 250,000,000 shares; (ii) approved an amendment to the A&R Certificate of Incorporation to reduce the vote required to amend, repeal, or adopt any provisions of the A&R Certificate of Incorporation from the approval of 66 2/3% of the voting power of the shares of the then outstanding voting stock of the Company entitled to vote to a majority of such shares; (iii) approved a reverse stock split of the Company's common stock at a ratio of between one-for-five and one-for-twenty-five, with such ratio to be determined at the sole discretion of the Company's Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion; (iv) approved if necessary, for purposes of complying with applicable Nasdaq Listing Rules, the potential issuance of more than 20% of the Company's issued and outstanding common stock in connection with the private placement of 4,205,406 shares of the Company's Series C Convertible Preferred Stock and unregistered warrants to purchase up to an aggregate of 6,078,125 shares of common stock; (v) approved if necessary, for purposes of complying with applicable Nasdaq Listing Rules, the potential issuance of more than 20% of the Company's issued and outstanding common stock in connection with the issuance of unregistered warrants to purchase up to an aggregate of 3,495,000 shares of common stock with respect to the waiver of certain rights of the purchaser signatories to those certain Securities Purchase Agreements, dated April 24, 2020, and June 1, 2020; and (vi) approved the adjournment of the Special Meeting for any purpose, including to solicit additional proxies in favor of the foregoing proposals if there were not sufficient votes to approve the foregoing proposals. The following is a tabulation of the voting on the proposals presented at the Special Meeting:

Proposal No. 1 - Increase of authorized shares of common stock

The amendment to the A&R Certificate of Incorporation to increase the number of authorized shares of common stock by 200,000,000 shares from 50,000,000 to 250,000,000 shares, was approved.